secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001818331-23-000060
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx Q2 2023: Exome/genome revenue up 36% YoY; cash burn down 36%
-------------------------------------------------------------------

- Continuing ops revenue $45.2M (+13% YoY); exome/genome rev. $28.7M (+36% YoY).
- Exome/genome volume 11,900 tests (+56% YoY); total tests ~55,000.
- Adj. gross margin 37% (pro forma), up from 34% in Q1; total adj. gross margin 42%.
- Adj. net loss $41.8M, improved 37% YoY; cash burn $53M, improved 36% YoY.
- FY2023 revenue guidance reaffirmed $205-220M; H2 cash use $70-85M; profitability target 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833123000060/0001818331-23-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833123000060/smfr-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001818331-23-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer